Overview
Asundexian is a next-generation anticoagulant developed by Bayer Pharmaceuticals. As a selective inhibitor of activated coagulation Factor XI (FXIa), it represents a novel approach to thrombosis prevention with potentially reduced bleeding risks compared to traditional anticoagulants like warfarin or direct oral anticoagulants (DOACs). The compound is currently in Phase II clinical trials for stroke prevention in atrial fibrillation and secondary prevention after acute myocardial infarction. This small-molecule drug belongs to the class of antithrombotic agents with a unique mechanism targeting the contact activation pathway of coagulation. Its development reflects the pharmaceutical industry's ongoing search for safer anticoagulation therapies that maintain efficacy while minimizing hemorrhagic complications.
Physical and Chemical Properties
Asundexian (BAY 2433334) is a synthetic organic compound with a molecular weight of 454.43 g/mol. The substance typically presents as a white to off-white crystalline powder with moderate solubility in dimethyl sulfoxide (DMSO) and limited aqueous solubility. Its chemical structure features a central pyridine core with fluorinated aromatic substituents and a tertiary amine group. The compound demonstrates stability under recommended storage conditions (-20°C in dry environment) but may degrade upon prolonged exposure to moisture or elevated temperatures. Analytical characterization typically employs HPLC with UV detection, with purity specifications exceeding 98% for research-grade material. The substance's logP value suggests moderate lipophilicity, contributing to its oral bioavailability.
Main Applications
Asundexian's primary therapeutic application focuses on cardiovascular medicine, specifically for stroke prevention in patients with atrial fibrillation and secondary prevention of thrombotic events following acute coronary syndromes. Clinical trials investigate its potential advantages over current standard therapies, particularly in reducing bleeding complications while maintaining antithrombotic efficacy. Beyond cardiovascular indications, preclinical studies explore its utility in venous thromboembolism prophylaxis and other conditions requiring anticoagulation. The drug's selective mechanism of action makes it particularly interesting for patients at high bleeding risk or those who have experienced bleeding complications on conventional anticoagulants. Ongoing research also examines potential applications in neuroprotection following ischemic stroke.
Safety and Storage
As a potent anticoagulant, Asundexian requires careful handling with appropriate personal protective equipment. The compound carries potential bleeding risks, and accidental exposure should be immediately treated with medical supervision. Laboratory personnel should avoid inhalation or direct contact with skin and eyes. For storage, the material should be kept in its original container at -20°C in a dry environment, with desiccant included if the container is frequently opened. Lyophilized formulations offer improved stability. The compound demonstrates photostability but should nevertheless be protected from prolonged light exposure. Proper inventory management should prevent expiration, with regular checks for any signs of degradation such as discoloration or clumping.
B2B Procurement Guide
Pharmaceutical companies and research institutions sourcing Asundexian should verify supplier credentials carefully, as the compound remains under patent protection and clinical development. Current procurement is primarily limited to certified research quantities from authorized distributors. Bulk quantities for clinical trial materials require direct negotiation with the manufacturer. Purchasers should expect stringent documentation requirements including end-use certificates and material transfer agreements. Lead times for custom synthesis orders typically range 8-12 weeks. For preclinical research, 10mg to 100mg quantities are commonly available at reference prices between $500-$1000 per 10mg, though costs may decrease as the compound advances through clinical development phases. Temperature-controlled shipping is mandatory for all orders.
Related Manufacturers
- 主营：古龙酸、6-疏基瞟呤、紫草素、Asundexian、6-氯嘌呤、菲啰嗪一钠盐、6-二氟-4-羟基苯腈
- 主营：Asundexian、实验试剂